{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:24Z","timestamp":1790983164530,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Bardet\u2013Biedl syndrome (BBS) is a genetically heterogeneous ciliopathy associated with hyperphagic obesity and kidney disease. Evidence on setmelanotide after pediatric kidney transplantation is limited. We evaluated two children with BBS treated with setmelanotide after kidney transplantation, collecting anthropometric, hunger, metabolic, graft-function, cyclosporine and genetic data. Patient 1, a 17-year-old boy with a homozygous pathogenic SDCCAG8 exon deletion, improved over 12 months: weight 55.6 to 48.0 kg, BMI 26.6 to 23.0 kg\/m2, BMI-for-age z-score +1.60 to +0.43, maximal-hunger score 8\/10 to 5\/10, and HbA1c 6.5% to 5.1%. Patient 2, an 8-year-old girl with a homozygous likely pathogenic BBS5 splice-site variant and a heterozygous PCSK1 N221D variant, showed reduced hunger and an initial z-score fall from +6.10 to +5.69 by month 2.5, meeting the 0.2-point threshold for clinically meaningful change; this was not sustained, and BMI rose from 38.0 to 42.7 kg\/m2 by eight months despite a dose of 3 mg\/day. Graft function and cyclosporine trough concentrations remained stable, and skin hyperpigmentation was the only treatment-related adverse effect. In these two patients, setmelanotide was not associated with graft deterioration or altered cyclosporine trough concentrations, although two cases cannot establish safety. The divergent trajectories highlight interindividual variability; the role of PCSK1 N221D remains uncertain, and these observations are hypothesis-generating.<\/jats:p>","DOI":"10.3390\/ijms27177740","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"7740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet\u2013Biedl Syndrome"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1709-4272","authenticated-orcid":false,"given":"Antonia","family":"Kondou","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-5893","authenticated-orcid":false,"given":"Pavlos","family":"Siolos","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4554-3116","authenticated-orcid":false,"given":"Georgia","family":"Sotiriou","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology and Diabetes Mellitus Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Agakidis","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-1766","authenticated-orcid":false,"given":"John","family":"Dotis","sequence":"additional","affiliation":[{"name":"Third Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4964-5726","authenticated-orcid":false,"given":"Athanasios","family":"Christoforidis","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology and Diabetes Mellitus Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-9285","authenticated-orcid":false,"given":"Nikoleta","family":"Printza","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, First Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ejhg.2012.115","article-title":"Bardet-Biedl syndrome","volume":"21","author":"Forsythe","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41431-024-01634-7","article-title":"Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations","volume":"32","author":"Dollfus","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/humu.23862","article-title":"Meta-analysis of genotype-phenotype associations in Bardet-Biedl syndrome uncovers differences among causative genes","volume":"40","author":"Niederlova","year":"2019","journal-title":"Hum. Mutat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM198910123211503","article-title":"The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome","volume":"321","author":"Green","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41588-017-0020-9","article-title":"Subcellular localization of MC4R with ADCY3 at neuronal primary cilia underlies a common pathway for genetic predisposition to obesity","volume":"50","author":"Siljee","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e142064","DOI":"10.1172\/JCI142064","article-title":"Melanocortin 4 receptor signals at the neuronal primary cilium to control food intake and body weight","volume":"131","author":"Wang","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: Single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Argente","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","article-title":"Setmelanotide for the treatment of acquired hypothalamic obesity: A phase 2, open-label, multicentre trial","volume":"12","author":"Roth","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S2213-8587(24)00273-0","article-title":"Setmelanotide in patients aged 2\u20135 years with rare MC4R pathway-associated obesity (VENTURE): A 1-year, open-label, multicenter, phase 3 trial","volume":"13","author":"Argente","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","unstructured":"European Medicines Agency (EMA) (2026, August 25). Imcivree: EPAR. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imcivree."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/ng.177","article-title":"Common nonsynonymous variants in PCSK1 confer risk of obesity","volume":"40","author":"Benzinou","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2337\/db11-0305","article-title":"Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity","volume":"61","author":"Creemers","year":"2012","journal-title":"Diabetes"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00467-017-3636-1","article-title":"Obesity in pediatric kidney transplant recipients and the risks of acute rejection, graft loss and death","volume":"32","author":"Ladhani","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Guo, D.-F., Cui, H., Zhang, Q., Morgan, D.A., Thedens, D.R., Nishimura, D., Grobe, J.L., Sheffield, V.C., and Rahmouni, K. (2016). The BBSome controls energy homeostasis by mediating the transport of the leptin receptor to the plasma membrane. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1005890"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/hmg\/ddp031","article-title":"Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling","volume":"18","author":"Seo","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ng.662","article-title":"Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy","volume":"42","author":"Otto","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41588-020-0707-1","article-title":"Evidence for secondary-variant genetic burden and non-random distribution across biological modules in a recessive ciliopathy","volume":"52","author":"Kousi","year":"2020","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41525-022-00311-2","article-title":"Allelic overload and its clinical modifier effect in Bardet-Biedl syndrome","volume":"7","author":"Solarat","year":"2022","journal-title":"npj Genom. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e184636","DOI":"10.1172\/JCI184636","article-title":"Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model","volume":"135","author":"Singh","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00467-016-3415-4","article-title":"Renal transplantation in Bardet-Biedl syndrome","volume":"31","author":"Haws","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41591-018-0015-9","article-title":"MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency","volume":"24","author":"Biebermann","year":"2018","journal-title":"Nat. Med."},{"key":"ref_23","unstructured":"ClinicalTrials.gov (2026, August 05). A Phase 2 Open-Label Study of Setmelanotide in Patients with Prader-Willi Syndrome, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06772597."},{"key":"ref_24","unstructured":"Miller, J.L., Graven, C., and Koren, D. (2026, January 13\u201316). Setmelanotide, a Melanocortin-4 Receptor Agonist, in Prader-Willi Syndrome: Initial Phase 2 Results. Presented at the ENDO 2026, Chicago, IL, USA. Abstract SAT-713."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:52:29Z","timestamp":1788256349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":24,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177740"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177740","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}